nt 4

Anti-Influenza agent 4 是一种有效且具有选择性的流感病毒 抑制剂，对A Parma 和 A Roma 毒株具有抑制作用， EC50 分别为 62 nM 和150 nM。

Anti-inflammatory agent 49 是一种高效的Drp1-Fis1相互作用的抑制剂，抑制 GTPase，可用于研究线粒体功能障碍引起的疾病。

Anticancer agent 46是一种有效的抗癌剂， 在细胞实验中显示出抗增殖活性，对 MGC803细胞的 IC50为0.986μM。

Anti-inflammatory agent 42 具有抗炎活性，抑制 LPS 刺激的巨噬细胞 TNF-α 和 IL-6 的表达。

Compound 42 (Compound 2) 作为一种有效的抗疟剂，能够在疟原虫Plasmodium falciparum的无性生殖阶段 (IC50<0.5μM) 和配子阶段 (IC50为 0.14 μM) 中显示出显著的抑制效果。

抗疟化合物43 (compound 16c) 针对3D7菌株展示出极高的活性，其IC50值仅为0.0151 μM。

Antimalarial agent 45 (compound 8I)，一种具有显著抗疟原虫活性的抗疟剂，其IC50为0.21 μM，主要用于疟疾相关的科学研究。

Antimalarial agent 44 (Compound 3)，一种高效抗寄生虫的抗疟化合物，显示在MDCK-MDR1细胞单层中具备出色的渗透能力，并在小鼠肝脏微粒体中表现出较高的清除率。

Antimalarial agent 46 (Compound 42a) 是一种具有抗疟活性的化合物，对P. falciparum lines表现出抑制效果。

Antimalarial agent 47 (compound F14) 是一种用于抗疟原虫的化合物，其对恶性疟原虫 W2 菌株的IC50值为235 nM。

Antimalarial agent 48 (Compound 15a) 是一种三嗪类化合物，具有抗疟疾活性，对Plasmodium falciparum K1 和 Plasmodium falciparum FCR3 的抑制浓度分别为 280 和 290 nM。Antimalarial agent 48 适合作为抗感染领域的研究对象。

Antibacterial agent 41 (example 3) is a antibacterial agent.

Antibacterial Agent 42 demonstrates potent antibacterial activity by effectively reducing the Minimum Inhibitory Concentration (MIC) of the broad-spectrum antibacterial agent Ceftazidime.

Antibacterial agent 43, is a potent antibacterial compound. It exhibits promising activity against bacterial infections and offers great potential for research purposes.

Antibacterial agent 44 is a novel antibacterial compound (WO2013030735A1, example 7). It exhibits potent antibacterial activity and is suitable for research purposes related to the study of bacterial infections.

Antibacterial Agent 45 (AA45) exemplifies a potent antibacterial compound that effectively reduces the minimal inhibitory concentration (MIC) value of Ceftazidime, another antibacterial agent.

Antibacterial agent 46, serves as a potent antibacterial compound. With its versatile properties, this agent demonstrates considerable potential for supporting research on bacterial infections.

Antibacterial Agent 47 demonstrates potent antibacterial activity as an adjunct therapy to parenteral antibiotic Ceftazidime. By effectively reducing the minimum inhibitory concentration (MIC) of Ceftazidime, Antibacterial Agent 47 acts as a highly promising antimicrobial agent, thereby enhancing the overall efficacy of the treatment.

Antibacterial agent 49 (example 12) is a antibacterial agent.

Antibacterial agent 40 is an antibacterial agent.

GABAA receptor agent 4 (compound 1e) 是有效的γ-GABAAR 拮抗剂 (Ki = 0.18 μM)。GABAA receptor agent 4 具有免疫调节潜力，已被证明有效地挽救了对 T 细胞增殖的抑制。

Anticancer agent 43 是一种有效的抗癌剂，通过 caspase 3， PARP1，Bax 蛋白依赖性途径诱导癌细胞凋亡 (apoptosis)。Anticancer agent 43 能够诱导 DNA 损伤，可用于研究大鼠胶质母细胞瘤 。

Anticancer agent 47 (compound 4j) exhibits potent anticancer properties, demonstrating antiproliferative activities and inducing apoptosis as well as cell cycle arrest at G0 G1 phase. Moreover, Anticancer agent 47 has exhibited significant in vivo antitumor activities [1].

Anticancer agent 42 (compound 10d) is an orally active, potent anticancer agent with demonstrated efficacy against MDA-MB-231 cells, exhibiting an IC50 of 0.07 μM. It exerts its anticancer activity through the activation of apoptotic pathways and p53 expression. Anticancer agent 42 is a valuable tool for investigating metastatic breast cancer [1].